Metabolic dysfunction–associated steatotic liver disease (MASLD) can progress silently, allowing liver scarring to develop before symptoms appear. Assessing MASLD fibrosis risk requires more than ALT and AST: these enzymes may reflect liver-cell injury, but they do not […]
